656 filings
Page 5 of 33
6-K
fd1u cw3bn8ipshw5y
29 Apr 22
Immutep Quarterly Activities Report & Appendix 4C
7:25pm
6-K
09c9u6h
28 Apr 22
Immutep to Announce New TACTI-002 Data
4:56pm
6-K
p7907cpx5px4a
30 Mar 22
Current report (foreign)
7:10pm
6-K
z72gd18rhkqp9b3xhros
24 Mar 22
Immutep announces publication of TACTI-002 abstract
6:39pm
6-K
k6b6 r16cg66a0zwf87
18 Mar 22
Immutep Announces Second Japanese Patent Grant for LAG-3 Antagonist Antibody LAG525
5:43pm
6-K
tl69mb
10 Mar 22
Immutep Receives Constructive Feedback from Us Fda on Its
5:07pm
6-K
w4ty6aif
24 Feb 22
Immutep Granted Australian Patent for Eftilagimod Alpha, a Soluble LAG-3 Protein, In Combination with a PD-1 Pathway Inhibitor
6:10am
6-K
reww0z3r no
24 Feb 22
Half-Year Financial Report
6:07am
6-K
zyxz j4e1cl
25 Jan 22
Immutep Quarterly Activities Report & Appendix 4C
4:56pm
6-K
uspkthdm y1xv
16 Dec 21
Current report (foreign)
6:04am
6-K
3ild xxnt4
3 Dec 21
Immutep Reports Good Safety from First Five Patients In Triple Combination Therapy Efti Study, INSIGHT-003
12:00am
6-K
tfjec1qfjm1 3csjo
22 Nov 21
Immutep Successfully Completes Recruitment for Phase II TACTI-002 Study
12:00am
6-K
dnfbqaa0w3yq6i9y
18 Nov 21
Current report (foreign)
12:00am
6-K
92byj
15 Nov 21
Current report (foreign)
4:38pm
6-K
o2fc mpcxd1
12 Nov 21
Immutep Announces Publication of AIPAC, TACTI-002 and TACTI-003 Abstracts
12:00am
6-K
02ke3j p6
3 Nov 21
Immutep Granted Chinese Patent for Eftilagimod Alpha, a Soluble LAG-3 Protein, In Combination with a Chemotherapy Agent
12:00am
6-K
m3aqyloj8jx9cu
29 Oct 21
Immutep receives positive EMA scientific advice for About Scientific Advice
6:05am
6-K
1a412
28 Oct 21
Immutep Quarterly Activities Report & Appendix 4C
10:15am
6-K
ogblwb
29 Sep 21
Immutep Receives A$3.4 million R&D Tax Incentive from French Government
6:44am